Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Sarcoma 1Breast 1

Conditions

Carcinoma, Merkel Cell 21Melanoma 9Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Skin Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Sezary Syndrome 1Sarcoma 1Primary Myelofibrosis 1Mycosis Fungoides 1Motor Activity 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 24Nivolumab 13atezolizumab 7Ipilimumab 6Cyclophosphamide 6fludarabine 5Specimen Handling 5Magnetic Resonance Spectroscopy 5aldesleukin 4Interleukin-2 4Biopsy 4durvalumab 3cemiplimab 3Docetaxel 3tislelizumab 2osimertinib 2fludarabine phosphate 2enzalutamide 2avelumab 2X-Rays 2Ritonavir 2Radiotherapy 2Observation 2Methods 2Immunoglobulin G 2IFL protocol 2Drug Therapy 2zimberelimab 1utomilumab 1ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × avelumab × Dermatologic × Clear all
NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡